Bioorganoids
Revolutionizing Cancer Drug Discovery with OrgCan™. Our Patient-Derived Cancer Organoids (PDCOs) bridge the gap between early research and clinical success.
Patient-Derived Excellence
Why human organoids for cancer research?
Patient Relevance
Directly derived from human donors for superior clinical predictability.
High Predictivity
Faithfully replicates patient response to drug candidates.
Accelerated Discovery
Shorten timelines from lead optimization to clinical trials.
Personalized Medicine
Models that capture the diversity of the human population.
Tumor Heterogeneity
Maintains the complex cellular composition of the original tissue.
Novel Biomarkers
Ideal for the discovery and validation of new clinical markers.
Cancer Organoids (PDCOs)
Breast
Skin
Ovarian
Colon
Oral
Prostate
Lung
Uteral
Bladder
Normal Tissue Organoids
Liver
Brain
Lung
Pancreas
Spleen
Prostate
Kidney
Colon
Bladder
Hair Follicle
High-fidelity cancer organoids derived from patient samples.
Featured Collection
Breast Cancer Patient-Derived Panel
Our specialized panel consists of organoids derived from 15 unique human breast cancer patients, capturing the wide spectrum of tumor subtypes and genetic variations.
- High-throughput screening (HTS) of large libraries
- Toxicity & Efficacy screening of candidate molecules
- Biomarker discovery & clinical validation
- Drug-Drug Interaction (DDI) & metabolism studies
- TME co-culture with immune and stromal cells
Partner for Precision Research
Leverage our OrgCan™ platform to validate your drug candidates in patient-relevant models before clinical trials.